Close
American Drug Delivery & Formulation Summit
Xylem

Agilent Technologies and Oxford Gene Technology Expand Microarray and Sequencing Partnership

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

TRT Safety: What Current Research Actually Says About Long-Term Use

Testosterone replacement therapy has spent years caught between two...

Merck Signs Voluntary Licensing Deals for Oral HIV Pill

Merck has entered into seven voluntary licensing agreements with...

Trump Proposes Generic Drug Tariffs to Drive Reshoring Effort

President Donald Trump announced plans to implement massive generic...
- Advertisement -

Agilent Technologies Inc. and Oxford Gene Technology today announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing.

Mike Evans, chief executive of OGT, said: “We are delighted to have been able to broaden our supply partnership with Agilent to include the industry-leading SureSelect platform for our recently launched Genefficiency next-generation sequencing service. We are also pleased to extend our OEM supply agreement for oligonucleotide microarrays, building on the success of our comprehensive CytoSure product range for cytogenetics.”

“Agilent and OGT have a very close working relationship and we are excited to expand our collaboration to the SureSelect platform under our Certified Services Provider program,” said Robert Schueren, vice president and general manager of Agilent’s genomics business. “OGT’s bioinformatics capabilities add significant value to customers targeting specific areas of the genome with our SureSelect product line.”

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

TRT Safety: What Current Research Actually Says About Long-Term Use

Testosterone replacement therapy has spent years caught between two...

Merck Signs Voluntary Licensing Deals for Oral HIV Pill

Merck has entered into seven voluntary licensing agreements with...

Trump Proposes Generic Drug Tariffs to Drive Reshoring Effort

President Donald Trump announced plans to implement massive generic...

What to Look for in a Supplement Manufacturer

Finding a supplement manufacturer is relatively easy. Finding one...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป